These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 7683625)

  • 21. Will it be another 20 years before Hodgkin lymphoma patients benefit from BEACOPP therapy?
    Diehl V; Engert A
    Nat Clin Pract Oncol; 2006 May; 3(5):227. PubMed ID: 16682982
    [No Abstract]   [Full Text] [Related]  

  • 22. Low acute hematological toxicity during chemotherapy predicts reduced disease control in advanced Hodgkin's disease.
    Brosteanu O; Hasenclever D; Loeffler M; Diehl V;
    Ann Hematol; 2004 Mar; 83(3):176-82. PubMed ID: 15064867
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The management of Hodgkin's disease with chemotherapy or combined modality treatment].
    Tsushita K; Utsumi M; Shimoyama M
    Gan To Kagaku Ryoho; 1998 Dec; 25(14):2202-9. PubMed ID: 9881076
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Greater curability in advanced Hodgkin's disease?
    Portlock CS
    Cancer J Sci Am; 1999; 5(5):264-5. PubMed ID: 10526665
    [No Abstract]   [Full Text] [Related]  

  • 25. Comparison of MOPP/MOPP +/- RT vs. MOPp/ABVD +/- RT in poor prognosis Hodgkin's disease. Long-term results.
    Comella P; Abate G; Fiore M; Di Finizio G; Frezza P; Scoppa G; Anania C; Coucourde F; Zarrilli D
    J Chemother; 1989 Jul; 1(4 Suppl):1254-6. PubMed ID: 16312855
    [No Abstract]   [Full Text] [Related]  

  • 26. [Comparison of preliminary results of involved-field with extended field radiotherapy combined with chemotherapy for early stage Hodgkin's disease].
    Wang WH; Li YX; Song YW; Jin J; Liu YP; Wang SL; Zhou LQ; Liu XF; Yu ZH; Han JZ
    Zhonghua Zhong Liu Za Zhi; 2006 Mar; 28(3):218-21. PubMed ID: 16875611
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group.
    Engert A; Schiller P; Josting A; Herrmann R; Koch P; Sieber M; Boissevain F; De Wit M; Mezger J; Duhmke E; Willich N; Muller RP; Schmidt BF; Renner H; Muller-Hermelink HK; Pfistner B; Wolf J; Hasenclever D; Loffler M; Diehl V;
    J Clin Oncol; 2003 Oct; 21(19):3601-8. PubMed ID: 12913100
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [High-dose chemotherapy and autologous stem cell transplantation for refractory and relapsing Hodgkin's disease as first-line therapy-- studies at Sheba Medical Center--Tel Hashomer].
    Avigdor A; Hardan I; Shpilberg O; Raanani P; Grotto I; Ben-Bassat I
    Harefuah; 2000 Sep; 139(5-6):174-9, 248, 247. PubMed ID: 11062945
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials.
    Noordijk EM; Carde P; Dupouy N; Hagenbeek A; Krol AD; Kluin-Nelemans JC; Tirelli U; Monconduit M; Thomas J; Eghbali H; Aleman BM; Bosq J; Vovk M; Verschueren TA; Pény AM; Girinsky T; Raemaekers JM; Henry-Amar M
    J Clin Oncol; 2006 Jul; 24(19):3128-35. PubMed ID: 16754934
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Outcome of 70 patients diagnosed with Hodgkin's disease after first-line and salvage treatment: experience at one center].
    Arranz R; Gil-Fernández JJ; Muñoz E; Acevedo A; Sobrino MP; Fernández-Rañada JM
    Sangre (Barc); 1998 Jun; 43(3):179-84. PubMed ID: 9741222
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of a modified Stanford V regimen in patients with advanced Hodgkin's lymphoma.
    Hohaus S; Di Febo A; Storti S; Teofili L; Voso MT; Leone G
    Haematologica; 2004 Jun; 89(6):751-2. PubMed ID: 15194545
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Feasibility study of application of international prognostic score on prediction of prognosis for advanced Hodgkin's lymphoma].
    Fu XH; Wang SS; Huang Y; Wang B; Huang HQ; Zhang L; Sun XF; Xu RH; Lin TY
    Ai Zheng; 2006 Aug; 25(8):1013-8. PubMed ID: 16965685
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pegfilgrastim support for full delivery of BEACOPP-14 chemotherapy for patients with high-risk Hodgkin's lymphoma: results of a phase II study.
    Engert A; Bredenfeld H; Döhner H; Ho AD; Schmitz N; Berger D; Bacon P; Skacel T; Easton V; Diehl V
    Haematologica; 2006 Apr; 91(4):546-9. PubMed ID: 16585019
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical dose-volume histogram analysis in predicting radiation pneumonitis in Hodgkin's lymphoma.
    Koh ES; Sun A; Tran TH; Tsang R; Pintilie M; Hodgson DC; Wells W; Heaton R; Gospodarowicz MK
    Int J Radiat Oncol Biol Phys; 2006 Sep; 66(1):223-8. PubMed ID: 16904523
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study.
    Engert A; Diehl V; Franklin J; Lohri A; Dörken B; Ludwig WD; Koch P; Hänel M; Pfreundschuh M; Wilhelm M; Trümper L; Aulitzky WE; Bentz M; Rummel M; Sezer O; Müller-Hermelink HK; Hasenclever D; Löffler M
    J Clin Oncol; 2009 Sep; 27(27):4548-54. PubMed ID: 19704068
    [TBL] [Abstract][Full Text] [Related]  

  • 36. What is the treatment of choice for advanced-stage Hodgkin's lymphoma: ABVD, Stanford V, or BEACOPP?
    Hehn ST; Miller TP
    Curr Hematol Rep; 2004 Jan; 3(1):17-26. PubMed ID: 14695845
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The risk of acute leukemia in patients treated for Hodgkin's disease is significantly higher aft [see bined modality programs than after chemotherapy alone and is correlated with the extent of radiotherapy and type and duration of chemotherapy: a case-control study.
    Brusamolino E; Anselmo AP; Klersy C; Santoro M; Orlandi E; Pagnucco G; Lunghi F; Maurizi-Enrici R; Baroni CD; Lazzarino M; Mandelli F; Bernasconi C
    Haematologica; 1998 Sep; 83(9):812-23. PubMed ID: 9825578
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Management of advanced, resistant Hodgkin's disease and non-Hodgkin's lymphoma: a phase II study.
    Williams SF; Ultmann JE; Gaynor E; Watson S
    Cancer Treat Rep; 1986 Aug; 70(8):1033-4. PubMed ID: 2425964
    [No Abstract]   [Full Text] [Related]  

  • 39. Eruptive pseudoangiomatosis in a child undergoing chemotherapy for Hodgkin lymphoma.
    Henry M; Savaşan S
    Pediatr Blood Cancer; 2012 Aug; 59(2):342-3. PubMed ID: 22184104
    [No Abstract]   [Full Text] [Related]  

  • 40. Intensive combination chemotherapy and X-irradiation in Hodgkin's disease.
    Moxley JH; De Vita VT; Brace K; Frei E
    Cancer Res; 1967 Jul; 27(7):1258-63. PubMed ID: 4952914
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.